Evidence map›Paper›PMID 39436613›Full record

ArticleJournal of patient-reported outcomes2024

Associations between symptom-based long COVID clusters and long-term quality of life, work and daily activities among individuals testing positive for SARS-CoV-2 at a national retail pharmacy.

Manuela Di Fusco, Joseph C Cappelleri, Alon Yehoshua, Kelly J Thomas Craig, Mary B Alvarez, Kristen E Allen, Thomas M Porter, Santiago M C Lopez, Laura Puzniak, Xiaowu Sun

Registry-linked trialAbstract read
In one paragraph

Article in Journal of patient-reported outcomes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05160636 (Patient-Reported Outcomes Associated With COVID-19 and Influenza), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05160636 active not recruitingnot on this map

Patient-Reported Outcomes Associated With COVID-19 and Influenza: A Prospective Survey Study on Outpatient Symptomatic Adults With Test-Confirmed Illness in the United States

TypeobservationalSponsorPfizerRan2022 to 2027Enrolled999ConditionsCOVID-19, Coronavirus Disease 2019, InfluenzaArmsCOVID-19 Vaccine
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Manuela Di FuscoPfizer Inc, New York, NY, USA. Manuela.difusco@pfizer.com.ORCID 0000-0003-0079-7331
Joseph C CappelleriPfizer Inc, New York, NY, USA.
Alon YehoshuaPfizer Inc, New York, NY, USA.
Kelly J Thomas CraigCVS Health, Woonsocket, RI, USA.
Mary B AlvarezPfizer Inc, New York, NY, USA.
Kristen E AllenPfizer Inc, New York, NY, USA.
Thomas M PorterPfizer Inc, New York, NY, USA.
Santiago M C LopezPfizer Inc, New York, NY, USA.
Laura PuzniakPfizer Inc, New York, NY, USA.
Xiaowu SunCVS Health, Woonsocket, RI, USA.

Funding

Pfizer Not applicable
6 · The paper itself

Abstract

backgroundEvidence on long COVID symptom clustering patterns among patients with COVID-19 is limited. We summarized long COVID symptoms in clusters defined by number of symptoms co-occurring together, and we assessed Health-Related Quality of Life (HQRoL), Work Productivity and Activity Impairment (WPAI) outcomes across these clusters over time. We assessed associations between the clusters and BNT162b2 vaccination status.

methodsA prospective longitudinal patient-reported outcomes (PRO) study recruited laboratory-confirmed symptomatic COVID-19 patients seeking testing from a national retail pharmacy. Long COVID-19 symptoms were self-reported by participants at 4-week, 3-month and 6-month surveys. Patient classes identified via latent class analysis (LCA) with long COVID-19 symptoms were simplified into clusters based on number of symptoms. HRQoL and WPAI outcomes were collected using EQ-ED-5L and WPAI: GH questionnaires. Mixed models for repeated measures analyses were conducted to examine associations between exposure groups and outcomes.

resultsThe study included 328 participants that were segmented into three groups of long COVID-19 symptoms based on LCA and then simplified by the number of symptoms (Cluster 1 low, <2; Cluster 2 moderate, 2-6; and Cluster 3 high, >6 symptoms). The number of long COVID-19 symptoms was negatively associated with HRQoL and WPAI, whereby participants with high symptom burden (>6 symptoms) had the lowest HRQoL and WPAI scores assessed by absenteeism, presenteeism, work productivity loss, activity impairment, and hours worked metrics. Compared with those unvaccinated and not up-to-date with COVID-19 vaccination, subjects boosted with BNT162b2 consistently reported less symptom burden during the follow-up, regardless of their symptom-based cluster.

conclusionThree distinct patient clusters based on frequency of long COVID symptoms experienced different HRQoL and WPAI outcomes over 6 months. The cluster with more concomitant symptoms experienced greater burden than the others. Participants up-to-date with BNT162b2 reported lower symptom burden across all clusters and timeframes. CLINICAL

trial registrationClinicaltrials.gov NCT05160636.

Indexed as

Activities of Daily LivingCOVID-19Quality of LifeSARS-CoV-2AbsenteeismAdultBNT162 VaccineEfficiencyFemaleHumansLongitudinal StudiesMaleMiddle AgedPatient Reported Outcome MeasuresPharmaciesPost-Acute COVID-19 SyndromeBNT162 VaccineBNT162b2COVID-19HRQoLHumanisticlong-COVID-19 symptomsQuality of lifeSARS-CoV-2WPAI

Identifiers

PMID39436613
PMCPMC11496399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.